Back to Authors

Lindia, Jill A.

A5113740659 | I1285764155

Mayo Clinic

Merck & Co., Inc., Rahway, NJ, USA (United States)

Citations 3

Long-term efficacy of pembrolizumab (pembro; MK-3475) in a pooled analysis of 655 patients (pts) with advanced melanoma (MEL) enrolled in KEYNOTE-001.

Journal of Clinical Oncology | April 19, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 9005-9005

10.1200/jco.2015.33.15_suppl.9005

Model-based analysis of the relationship between pembrolizumab (MK-3475) exposure and efficacy in patients with advanced or metastatic melanoma.

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 3068-3068

10.1200/jco.2015.33.15_suppl.3068

Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma

JAMA | April 19, 2016 | Volume: 315 | Issue: 15 | Pages: 1600

10.1001/jama.2016.4059 | PMID 27092830